214 related articles for article (PubMed ID: 20085496)
1. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
[TBL] [Abstract][Full Text] [Related]
2. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
3. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
[TBL] [Abstract][Full Text] [Related]
4. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Arinze F; Shaver A; Raffanti S
Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening of Acyclovir Derivatives as Potential Antiviral Agents: Design, Synthesis, and Biological Evaluation of New Acyclic Nucleoside ProTides.
Derudas M; Vanpouille C; Carta D; Zicari S; Andrei G; Snoeck R; Brancale A; Margolis L; Balzarini J; McGuigan C
J Med Chem; 2017 Sep; 60(18):7876-7896. PubMed ID: 28829913
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir.
Balzarini J; Haller-Meier F; De Clercq E; Meier C
Antivir Chem Chemother; 2001 Sep; 12(5):301-6. PubMed ID: 11900349
[TBL] [Abstract][Full Text] [Related]
7. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
[TBL] [Abstract][Full Text] [Related]
8. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
9. Activity of penciclovir in antiviral assays against herpes simplex virus.
Bacon TH; Howard BA; Spender LC; Boyd MR
J Antimicrob Chemother; 1996 Feb; 37(2):303-13. PubMed ID: 8707740
[TBL] [Abstract][Full Text] [Related]
10. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.
Barnabas RV; Celum C
Curr HIV Res; 2012 Apr; 10(3):228-37. PubMed ID: 22384842
[TBL] [Abstract][Full Text] [Related]
11. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Andrei G; Gillemot S; Topalis D; Snoeck R
J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
[TBL] [Abstract][Full Text] [Related]
12. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
[TBL] [Abstract][Full Text] [Related]
13. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
[TBL] [Abstract][Full Text] [Related]
14. Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus.
Hostetler KY; Parker S; Sridhar CN; Martin MJ; Li JL; Stuhmiller LM; van Wijk GM; van den Bosch H; Gardner MF; Aldern KA
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11835-9. PubMed ID: 8265634
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
[TBL] [Abstract][Full Text] [Related]
16. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
17. A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.
Balzarini J; Andrei G; Balestra E; Huskens D; Vanpouille C; Introini A; Zicari S; Liekens S; Snoeck R; Holý A; Perno CF; Margolis L; Schols D
PLoS Pathog; 2013; 9(7):e1003456. PubMed ID: 23935482
[TBL] [Abstract][Full Text] [Related]
18. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
Eide K; Moerdyk-Schauwecker M; Stein DA; Bildfell R; Koelle DM; Jin L
Antivir Ther; 2010; 15(8):1141-9. PubMed ID: 21149921
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.
Henao-Martínez AF; Weinberg A; Waldman WJ; Levi ME
J Clin Virol; 2012 Jul; 54(3):276-8. PubMed ID: 22465339
[TBL] [Abstract][Full Text] [Related]
20. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
